The second section of our Special Task Force builds on the discussion of value and perspective in the previous article of the report by 1) defining a health economics approach to the concept of value in health care systems; 2) discussing the relationship of value to perspective and decision context, that is, how recently proposed value frameworks vary by the types of decisions being made and by the stakeholders involved; 3) describing the patient perspective on value because the patient is a key stakeholder, but one also wearing the hat of a health insurance purchaser; and 4) discussing how value is relevant in the market-based US system of mixed private and public insurance, and differs from its use in single-payer systems. The five recent value frameworks that motivated this report vary in the types of decisions they intend to inform, ranging from coverage, access, and pricing decisions to those defining appropriate clinical pathways and to supporting provider-clinician shared decision making. Each of these value frameworks must be evaluated in its own decision context for its own objectives. Existing guidelines for cost-effectiveness analysis emphasize the importance of clearly specifying the perspective from which the analysis is undertaken. Relevant perspectives may include, among others, 1) the health plan enrollee, 2) the patient, 3) the health plan manager, 4) the provider, 5) the technology manufacturer, 6) the specialty society, 7) government regulators, or 8) society as a whole. A valid and informative costeffectiveness analysis could be conducted from the perspective of any of these stakeholders, depending on the decision context.
Introduction
This section builds on the discussion of value and perspective in the introduction by Neumann et al. [1] by 1) defining a health economics approach to the concept of value in health care systems; 2) discussing the relationship of value to perspective and how recently proposed value frameworks vary by the types of decisions being made-what we call "decision context"-and by the stakeholders involved in those decisions; 3) describing the patient perspective on value because the patient is a key stakeholder, but one also wearing the hat of a health insurance purchaser; and 4) discussing how value is relevant in the market-based US system of mixed private and public insurance, and differs from its use in single-payer systems.
Defining Value
Given the focus of our Special Task Force (STF) on US value assessment frameworks that exist in a mixed private and public health insurance system with a market orientation, our approach follows basic accepted principles of microeconomics, even as we recognize 1) certain limitations of these principles, particularly in relation to health care markets, and 2) the need to consider important issues, such as equity, that are not traditionally the focus of economics and are addressed by other disciplines. First, "value" is defined here from an economic perspective: the "gross value" can be thought of what someone would be willing to pay for an economic good or intervention, whereas the "net value" subtracts the opportunity cost incurred to obtain that gross value.
In other words, the net value is what a consumer would be willing to pay to avoid losing access to the good. Second, because individuals vary in their preferences for health and other economic goods, the value they place on different health care interventions will also vary. Third, given that most medical care is purchased indirectly via health insurance, individuals do not directly face prices, and their agents (insurers and providers) acting on their behalf must assess value for money. Indeed, this is a large part of the motivation for payers and providers to develop value frameworks. Sometimes US payers have established price schedules (e.g., Medicare physician fee schedules or prospective payment by diagnosis-related groups), although their link to value is arguably tenuous.
The concepts of value and efficiency are related in economics, but the relationship can be complicated and nuanced with respect to health care technologies-and notably for innovative medicines. For economic assessment purposes, the net value of an action, a program, a treatment, or a technology reflects the willingness to pay (WTP) for the improvement in well-being minus the opportunity cost of resources used to produce that improvement. Broadly, achieving "economic efficiency" is obtaining maximum value for the money spent. In assessing value and economic efficiency from the perspective of society as a whole, both the well-being (utility) and the cost measures should include the consequences to all those affected by the action [2] .
For well-known reasons, directly assessing benefits and costs of health care in strictly monetary terms using observed market prices is fraught with difficulty given the market distortions (such as insurance), as noted earlier. Cost-effectiveness analysis (CEA), by relating an intervention's cost to its effectiveness (in terms of some change in health) as a ratio, is thus a standard approach to measuring the net value of a health care intervention. Economic efficiency is also sometimes considered in the short-term (static efficiency) and in the long-term (dynamic efficiency). Static efficiency means, for example, achieving the maximum expected health gain from a fixed annual budget; dynamic efficiency is about achieving the optimal rate of innovation. They are related in that paying for what people value provides the incentive to direct research and development to produce innovations that generate that value [3] . Because a simple comparison of marketbased monetary benefits and costs is not feasible or useful for most individual health care technologies, health economists and outcomes researchers have developed a work-around that allows comparisons among technologies in terms of incremental costeffectiveness ratios, and in comparison with a threshold of WTP or opportunity cost [4] [5] [6] .
Empirical studies document what is known intuitively about heterogeneous preferences for health care. Our fellow citizens attach different values to health outcomes. Two patients might value the same health gain differently, and some of this variation is related to differences in incomes, but much of it is related to differences in preferences about spending on the health care versus other non-health-related goods that they value. There is also variation across people in the extent to which they are willing to trade off extensions in life expectancy against various aspects of the quality of life. Nevertheless, the larger concern in heterogeneity is the health gain delivered from the same intervention in different subpopulations. This heterogeneity of treatment effect implies that it is inappropriate to try to determine a single value for a medical intervention; rather, we should seek to know the distribution of values in a population. Payment and reward systems for medical products and services are, however, typically based on population averages, and hence cannot fully reflect this variation in value.
The theoretical foundations chapter of the recently published report [2] of the Second Panel on Cost-Effectiveness in Health and Medicine posits that alternative microeconomic approaches are variants of the general principle of "constrained optimization," in particular, the maximization of health (a form of extra-welfarism) [7] or the maximization of individual well-being (traditional welfare economics) subject to a budget constraint [4] . Our STF follows a welfare economics approach in considering US value frameworks, recognizing that there is no fixed annual global budget for all of health care in the United States. At the same time, there are clearly more specific resource constraints and opportunity costs that apply over time in obtaining care for health plan members. Moreover, in public programs such as Medicaid or for public payers with short-term time horizons, there may effectively be a fixed annual budget.
